Preventing and Treating Hepatitis Infections in Stem Cell Transplant Recipients
Author Information
Author(s): Chakrabarti Suparno, Mukherjee Somnath, Manashi Chakrabarti
Primary Institution: Manashi Chakrabarti Foundation For Blood Disorders, Kolkata, INDIA
Hypothesis
What are the best strategies for preventing and treating hepatitis B and C infections in hematopoietic stem cell transplant recipients?
Conclusion
Effective prevention and management strategies can minimize complications and improve outcomes for stem cell transplant recipients infected with hepatitis B and C.
Supporting Evidence
- Over 350 million people are HBV carriers worldwide, with varying prevalence across regions.
- HBV reactivation post-transplant can lead to severe complications if not monitored closely.
- Preemptive antiviral therapy can significantly reduce the incidence of HBV reactivation.
Takeaway
Hepatitis B and C can cause serious problems for patients who receive stem cell transplants, but there are ways to prevent and treat these infections to help keep patients safe.
Methodology
The article reviews current guidelines and recommendations for screening, prevention, and treatment of hepatitis infections in stem cell transplant recipients.
Limitations
Limited data on the long-term effects of hepatitis infections in stem cell transplant recipients and the effectiveness of newer antiviral agents.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website